NOTICE OF MAILING CHANGE
☐ Check here if you wish to discontinue receiving this publication

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Distribution Center
National Institutes of Health
Room B3BE07, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, $500

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

VOL. 16, NO. 38 - NOVEMBER 20, 1987
NOTICES

REVISION OF RESEARCH CAREER DEVELOPMENT GUIDELINES--REMINDER......................................................... 1
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

PRIMATE TISSUE BANKING AND DISTRIBUTION PROGRAM.......................................................... 1
Division of Research Resources
Index: RESEARCH RESOURCES

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

SUPERCOMPUTING RESOURCES AND TRAINING AVAILABLE TO BIOMEDICAL RESEARCHERS AT THE PITTSBURGH SUPERCOMPUTING CENTER...................................................... 1
Division of Research Resources
Index: RESEARCH RESOURCES

PROPHYLACTIC PENICILLIN IN SICKLE CELL DISEASE: CENTRAL LABORATORY (RFP). ........................................... 2
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

CLINICAL STUDIES OF SAFETY AND EFFECTIVENESS OF ORPHAN PRODUCTS (RFA). ............................................. 2
Food and Drug Administration
Index: FOOD AND DRUGS

PROGRAMS OF EXCELLENCE FOR BASIC RESEARCH ON AIDS (REVISED RFA).................................................. 4
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

SPECIAL INTERNATIONAL POSTDOCTORAL RESEARCH PROGRAM IN ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) (REVISED RFA).................................................. 4
Fogarty International Center
Index: FOGARTY INTERNATIONAL CENTER

ALCOHOL RESEARCH CENTER GRANT ON ALCOHOL AND IMMUNOLOGIC DISORDERS (INCLUDING ACQUIRED IMMUNODEFICIENCY SYNDROME - AIDS) (RFA). ............... 5
International Research and Awards Branch
Index: ALCOHOL ABUSE AND ALCOHOLISM

RESEARCH LEADING TO AN ACCELERATED DECLINE IN TUBERCULOSIS MORTALITY AND MORBIDITY (RFA).................................................... 7
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

ONGOING PROGRAM ANNOUNCEMENTS

PREVENTION OF GALLSTONES (PA).................................................. 8
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RESEARCH CENTER GRANTS (PA)........................................... 10
National Institute of Mental Health
Index: MENTAL HEALTH
NOTICES

REVISION OF RESEARCH CAREER DEVELOPMENT AWARD GUIDELINES—REMINDER

P.T. 34; K.W. 1014002, 0710030

National Institutes of Health

As announced in the August 7, 1987 edition of the NIH Guide for Grants and Contracts (Vol. 16, No. 27), the National Institutes of Health recently revised its guidelines for the Research Career Development Award (RCDA). The revised guidelines are in effect for the February 1, 1988 application receipt date and all subsequent receipt dates. Prospective applicants should review the revisions and contact the NIH staff listed in the August 1987 announcement before submitting an application.

Copies of the full text of the revised guidelines, including a list of NIH staff contacts, are available from either of the following:

Office of Grants Inquiries
Division of Research Grants
Westwood Building, Room 449
Bethesda, Maryland 20892
Telephone: (301) 496-7441

Mr. Nicholas C. Moriarty
Westwood Building, Room A-27
Bethesda, Maryland 20892
Telephone: (301) 496-7221

PRIMATE TISSUE BANKING AND DISTRIBUTION PROGRAM

REVISION OF RESEARCH CAREER DEVELOPMENT GUIDELINES—REMINDER

P.T. 34; K.W. 0780020, 1014002

Division of Research Resources

The Tissue Banking and Distribution Program at the University of Washington Regional Primate Research Center provides tissue and fluid specimens from macaques and baboons. Viable specimens in culture media are prepared for shipment in less than an hour and delivered to most laboratories in the U.S. within 24 hours. Deliveries of quick-frozen or fixed specimens are made on a scheduled basis. More specialized preparations are supplied on request. A clinical and experimental history of the donor animal accompanies each specimen.

This Tissue Banking and Distribution Program is partially supported by the Division of Research Resources, NIH.

For more information, call or write:

Ms. Karlissa Foy
Tissue Program Coordinator
Regional Primate Research Center, SJ-50
University of Washington
Seattle, Washington 98195
Telephone: (206) 543-6999

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

SUPERCOMPUTING RESOURCES AND TRAINING AVAILABLE TO BIOMEDICAL RESEARCHERS AT THE PITTSBURGH SUPERCOMPUTING CENTER

P.T. 34; K.W. 1004000, 0780010

Division of Research Resources

Application Receipt Date: January 8, 1988

Grants are available to enable biomedical researchers to use the Cray X-MP/48 at the Pittsburgh Supercomputing Center (PSC) through a program funded by the Biomedical Research Technology Program, Division of Research Resources.
Starter grants of 3 service units (roughly 3 hours of single-processor X-MP time) are available for feasibility studies or code conversion and optimization. A limited number of larger grants of 20 service units are also available to experienced supercomputing researchers. Prospective grantees should demonstrate a need for supercomputing facilities; the proposed research must be biomedical and non-proprietary; grantees must be faculty members or post-doctoral fellows. Graduate students may be designated as users on any grant.

TRAINING

A four and a half day workshop on supercomputing techniques for biomedical researchers will be held from February 22 through 26, 1988. The workshop is aimed at experienced FORTRAN programmers, but prior supercomputing experience is not necessary. The topics include an introduction to VMS (optional), the Cray-VAX interface, Cray job control, Cray optimization techniques, an overview of available biomedical software, and a description of access paths to the PSC.

Expenses for this workshop are covered under a grant from the NIH. A limited number of openings for industrially-based biomedical researchers may be available for a fee of $1000. THE DEADLINE FOR APPLICATIONS IS JANUARY 8, 1988.

For application forms and additional information, call or send mail to:

Wendy Janocha
Biomedical Coordinator
Pittsburgh Supercomputing Center
4400 Fifth Avenue
Pittsburgh, PA 15213
Telephone: (412) 268-5005.

PROPHYLACTIC PENICILLIN IN SICKLE CELL DISEASE: CENTRAL LABORATORY

RFP AVAILABLE: RFP-NIH-NHLBI-HB-88-02
P.T. 34; K.W. 0740005, 0755010, 0780010
National Heart, Lung, and Blood Institute

The Sickle Cell Disease Branch of the Division of Blood Diseases and Resources of the National Heart, Lung, and Blood Institute has a requirement for a central laboratory to provide determinations of antibody titers to Streptococcus Pneumoniae on approximately 500 children enrolled in this study. The purpose of the study is to determine when prophylactic penicillin can be safely discontinued at five years of age in children with sickle cell anemia. Experience in immunologic aspects of sickle cell disease is required.

RFP NIH-NHLBI-HB-88-02 will be available on or about November 30, 1987, with proposals due on or about January 14, 1988. One (1) award is anticipated for a seven-year period. Your written request should include three (3) self-addressed mailing labels and must cite RFP No. NHLBI-HB-88-02.

Requests for copies of the RFP should be sent to the following address:

Lynda A. Bindseil, Contract Specialist
BDR Contract Section, Contracts Operations Branch, DEA
National Heart, Lung, and Blood Institute
Federal Building, Room 5C14
Bethesda, Maryland 20892

CLINICAL STUDIES OF SAFETY AND EFFECTIVENESS OF ORPHAN PRODUCTS

RFA AVAILABLE: Docket No. 87N-0267
P.T. 34; K.W. 0755015, 0740025, 0735000
Food and Drug Administration

Application Receipt Date: January 25, 1988

The Food and Drug Administration (FDA) is announcing the anticipated availability of funds for Fiscal Year 1988 for awarding grants to support clinical trials on safety and effectiveness of orphan products.
BACKGROUND

FDA has established the Office of Orphan Products Development to identify and facilitate the availability of orphan products. Orphan products are drugs, biologics, medical devices (including in vitro diagnostics), foods for medical purposes, and veterinary products that may be useful in an uncommon or common disease but lack committed commercial sponsorship because they are not considered commercially attractive for marketing. A subcategory of orphan products are those marketed products for which there is evidence suggesting usefulness in an uncommon, serious disease but which are not labeled for that disease because substantial evidence of safety and effectiveness for that use is lacking.

All funded studies are subject to the requirements of the Federal Food, Drug and Cosmetic Act and regulations promulgated thereunder.

In general, FDA will only consider awarding grants to support clinical studies for determining whether the products are safe and effective for premarket approval. These clinical studies may be designed to assist in the approval of unapproved products or of unapproved new uses for already marketed products.

Applications should be for one discrete clinical trial. The applicant must provide supporting evidence that the product to be investigated is available to the applicant in the form needed for the clinical trial.

In addition to FDA's general interest in clinical studies for the safety and effectiveness of orphan products, the agency has recognized the following areas of pediatric research for which applications are encouraged:

Studies on marketed drugs currently labeled only for adult uses which would provide data to support labeling these drugs for important uses in pediatric patients.

Research to develop nutritional products (medical foods) for management of inborn errors of metabolism for which adequate therapies are not currently available.

MECHANISM OF SUPPORT

Support will be in the form of grant awards which will be subject to all policies and requirements that govern the research grant programs of the Public Health Service.

REVIEW PROCEDURES

All applications responding to this request for applications will be reviewed and evaluated for scientific and technical merit by experts in the subject field of the specific application. The applications will also be subject to a second level of review to evaluate them in light of the aims of the Orphan Products Development Program.

METHOD OF APPLYING

Potential applicants should write or phone the individual listed below for the full RFA document, which includes instructions for the submission of applications:

Carol A. Wetmore
Food and Drug Administration
Office of Orphan Products Development, HF-35
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-4903

Applications must be submitted to the Food and Drug Administration using Form 398 (Rev. 9/86). The outside of the mailing package and the top of the application face page should be labeled "Response to RFA-FDA-OP-88-1."
PROGRAMS OF EXCELLENCE FOR BASIC RESEARCH ON AIDS

REVISED RFA AVAILABLE: 88-AI-01

P.T. 34; K.W. 0715120, 0715125, 0710070, 1002045, 1002004, 1002008

National Institute of Allergy and Infectious Diseases

In the October 16, 1987 issue of the NIH GUIDE FOR GRANTS AND CONTRACTS, Vol. 16, No. 34, the National Institute of Allergy and Infectious Diseases announced an RFA on PROGRAMS OF EXCELLENCE FOR BASIC RESEARCH ON AIDS (PEBRA). In that announcement, NIAID stated that the PEBRA program would be supported through the cooperative agreement mechanism.

NIAID wishes to announce that it is changing the mechanism of support of PEBRAs to the program project grant mechanism. Appropriate revisions will be made in the full RFA to reflect this change. For clarification, or to get a copy of the full revised RFA, contact:

Martin Padarathsingh, Ph.D.
Chief, Pathogenesis Branch
AIDS Program
NIAID, NIH
Westwood Building, Rm. 7A-04
Bethesda, MD 20892
Telephone: (301) 496-8378

SPECIAL INTERNATIONAL POSTDOCTORAL RESEARCH PROGRAM IN ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

RFA AVAILABLE: 87-TW-01

P.T. 22; K.W. 0715120, 0710030

Fogarty International Center

Application Receipt Date: January 22, 1988

[This is a revision of an announcement that appeared in this Guide on May 8, 1987 (Vol. 16, No. 16). The requirements for: (1) equal number of U.S. and foreign scientists and (2) full range of clinical and basic science disciplines have been relaxed. In addition the Fogarty International plans to make six (6) awards rather than two (2) awards].

Applicants who submitted applications for the September 15, 1987 receipt date need not reapply.

The Fogarty International Center invites applications from U.S. institutions with interest in developing multi-disciplinary postdoctoral fellowship programs in AIDS research for U.S. and foreign scientists. Funds will be awarded to encourage basic and clinical research in all biomedical and behavioral disciplines related to AIDS. Applications received in response to this request will be reviewed and considered for funding in a single competition.

BACKGROUND

According to the World Health Organization, 100 nations from all continents have reported AIDS cases in their countries. The current doubling time of new cases reported in the United States is approximately 15 months. Research into this disease has been significant. The causative agent, Human T-Lymphotropic Virus Type III/ Lymphadenopathy-Associated Virus (The name Human Immunodeficiency Virus (HIV) has been proposed for these viruses by the International Committee on the Taxonomy of viruses.) has been identified; the virus has been shown to severely impair the immune system and the central nervous system; the associated risk factors and major modes of transmission are known; and the epidemiologic patterns and modes of transmission have been shown to vary between men and women and among countries. Until the disease can be prevented, cures are found, or an effective vaccine is developed, AIDS will continue to be an increasingly global public health problem.

International cooperation is important in understanding and preventing AIDS. It is in this context that the Fogarty International Center, NIH, is initiating a Special International Postdoctoral Research Program in AIDS.
OBJECTIVES AND SCOPE

The objectives of the special institutional research fellowship program are (1) to support collaborative research between U.S. and foreign scientists who wish to enhance their knowledge and skills in the epidemiology, diagnosis, prevention, and treatment of AIDS and (2) to stimulate scientists from nations affected by AIDS to cooperate and to share research knowledge in combating this global problem.

It is expected that the program director will be a recognized scientist in AIDS research, interested in both the basic and clinical aspects of the syndrome, and able to attract as preceptors basic and clinical scientists in his or her institution who are experts in other biomedical and behavioral disciplines related to AIDS.

Under this award the program director will make fellowship appointments to U.S. and foreign scientists varying from 3-24 months. Scientists who are appointed must have an earned doctoral degree (M.D., Ph.D., D.V.M., D.D.S., D.O., D.P.M., O.D., Sc.D., D.Eng., D.N.S.) or the equivalent in a health science field, be actively engaged in AIDS research, not be employed by a for-profit institution, and if foreign, must have a permanent position in his/her home institution. Postdoctoral scientists at all career levels are eligible for appointment. It is expected that appointments will cover scientific disciplines related to AIDS research.

U.S. scientists from the grantee institution will be limited to collaborative study in foreign institutions only. The U.S. appointees must have a letter of invitation from the foreign hosts accepting the fellows and committing the resources of the foreign institutions to the research effort. Foreign scientists will be required to conduct their research at the awardee institution only: each appointee will be assigned to a preceptor from among the participating faculty. Sixty (60) months of appointments will be permitted each budget year.

STAFF CONTACT

For further information and a copy of the RFA contact:

Bettie J. Graham, Ph.D.
Chief
International Research and Awards Branch
Building 38A, Room 613
Fogarty International Center
National Institutes of Health
Bethesda, MD 20892
Telephone: (301) 496-6688

The RFA label provided with the instructions must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

ALCOHOL RESEARCH CENTER GRANT ON ALCOHOL AND IMMUNOLOGIC DISORDERS (INCLUDING ACQUIRED IMMUNODEFICIENCY SYNDROME - AIDS)

RFA AVAILABLE: AA-88-01

P.T. 04; K.W. 0404003, 0710070, 0715120

National Institute on Alcohol Abuse and Alcoholism

Application Receipt Date: April 1, 1988

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is interested in receiving grant applications for Centers to investigate various aspects of the relationship between alcohol, immune system alterations and infectious diseases, with special attention on acquired immunodeficiency syndrome (AIDS) and human immunodeficiency virus (HIV). The research program should include interrelated studies focusing on problems which have the potential for producing significant scientific information related to alcohol and immunologic disorders, including AIDS and HIV. Research conducted within the Center must be clearly related to problems concerning alcohol's interaction with the immune system and the role of alcohol as a cofactor in the development of infectious diseases and immune disorders.
BACKGROUND

The Alcohol Research Center Grants Program is designed to complement the regular research grants program of the NIAAA by providing long-term (typically for 5 years) support for interdisciplinary research programs with a distinct focus on a particular research theme relating to alcoholism, alcohol abuse, and alcohol-related problems. The program is intended to help attract the best scientists from biomedical, behavioral, and social science disciplines to work on research problems related to alcohol abuse and alcoholism and to provide a stable environment for such persons to engage in alcohol research in a coordinated and integrated fashion. A Center is expected to be a source of excellence in research and, through sustained excellence, to become a significant regional or national research resource. In addition, the applicant institution is expected to afford opportunities for training to persons from various disciplines and professions for research careers in alcoholism problems.

MECHANISM OF SUPPORT

Support for this program will be through the Specialized Research Center grant. Center grants are awarded to an institution in behalf of a Center Director for the support of broadly based multidisciplinary long-term research effort consisting of several major research components. Each component is expected to contribute to, and be directly related to, the effects of alcohol on the immune system and alcohol as a possible cofactor in the acquisition of infectious diseases, especially as related to AIDS and HIV.

APPLICATION AND REVIEW PROCEDURES

Application Form PHS-398 (Revised 9/86) is to be used. Application kits containing the necessary forms and general instructions may be obtained from business offices or offices of sponsored research at most universities, colleges, medical schools, and other major research facilities, or by contacting the NIAAA staff person as noted below.

Applications should be completed by following the General Instructions contained in the application kit and "Special Instructions for Preparing an Alcohol Research Center Grant Application," which will be made available upon request from the NIAAA. Applications should be completed in accordance with the page limitations noted in the Special Instructions. The RFA label available in the September 1986 revision of the application Form PHS 398 must be affixed to the bottom of the face page of the completed original application. Failure to use this label and to follow the general and special instructions could result in delayed processing of the application such that it may not reach the review committee in time for review.

The signed original and four permanent legible copies of the application should be sent to:

Grant Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
5333 Westbard Avenue
Bethesda, Maryland 20892-4500

In addition, two copies should be sent directly to:

Office of Scientific Affairs
National Institute on Alcohol Abuse and Alcoholism
Parklawn Building, Room 16C-20
5600 Fishers Lane
Rockville, Maryland 20857

Final review by the National Advisory Council on Alcohol Abuse and Alcoholism will be completed at its meeting in September 1988 and awards will be made no later than September 30, 1988. Applications will be accepted only for a single receipt date of April 1, 1988. The Institute requests a letter of intent by February 15, 1988.
Before preparing an application, potential applicants are advised to seek more specific information by contacting:

Albert A. Pawlowski, Ph.D.
Associate Director
Division of Basic Research
National Institute on Alcohol Abuse and Alcoholism
Parklawn Building, Room 14C-20
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-1273

This program is described in the Catalog of Federal Domestic Assistance No. 13.891, National Alcohol Research Centers Program. Grants to establish Alcohol Research Centers are authorized by Sections 301 and 511 of the Public Health Service Act. Regulations governing this program are contained at 42 CFR Part 54a, Subpart E, of the Code of Federal Regulations. This program is not subject to the intergovernmental review requirements of Executive Order 12372 as implemented through HHS regulations at 45 CFR Part 100.

RESEARCH LEADING TO AN ACCELERATED DECLINE IN TUBERCULOSIS MORTALITY AND MORBIDITY

RFA AVAILABLE: 88-AI-02

P.T. 34; K.W. 0715165, 0715125, 0710065, 1002027, 0755035

National Institute of Allergy and Infectious Diseases

Application Receipt Date: February 17, 1988

BACKGROUND INFORMATION

The National Institute of Allergy and Infectious Diseases (NIAID) supports research aimed at decreasing the mortality and morbidity from tuberculosis and ultimately eliminating this ancient disease from the United States and the world. Toward this end NIAID desires to expand its support of tuberculosis research.

RESEARCH GOALS AND SCOPE

Studies of interest include, but are not limited to, the following as they relate to the elimination of tuberculosis:

- The characteristics of the organism which are relevant to infectivity, pathogenicity, and immunogenicity, including specific components such as virulence factors, physiologic differences between virulent and avirulent tubercle bacilli, phenotypic changes that may occur during in vivo growth which contribute to virulence.

- The uptake and microenvironmental distribution of tubercle bacilli within macrophages, the effect on the bacilli of the recently recognized different populations of lymphocytes and macrophages having distinctively different functions, the development of new quantitative methods for determining the intraphagolysosomal events leading to bacterial inactivation.

- The host cellular and humoral factors which affect susceptibility and resistance to infection and disease from the tubercle bacilli, the modification of the host immune response, the modification of the host-parasite relationship to M. tuberculosis.

- The molecular cloning of protein antigens combined with T-cell cloning to arrive at the antigens responsible for cell mediated immunity and protective immunity in tuberculosis, development of adjuvants or immunomodulators with the capability of enhancing the protective efficacy of a sub-unit vaccine.

MECHANISM OF SUPPORT

Applications considered appropriate responses to this announcement are the traditional research project grants (RO1). The NIAID plans to support at least ten awards contingent on the overall merit of the proposed research and the availability of funds. Up to five years of support is anticipated.

The initial review for scientific and technical merit will be made by a review group to be convened by the Program Project Review Branch, NIAID; secondary
review will be by the National Advisory Allergy and Infectious Diseases Council. Funding decisions will be based upon relative scientific merit, program relevance, and the availability of appropriated funds.

STAFF CONTACT

A more detailed RFA may be obtained from:

Darrel D. Gwinn, Ph.D.
Tuberculosis Program Officer
Bacteriology and Virology Branch
National Institutes of Health
Westwood Building, Room 738
Bethesda, Maryland 20892
Telephone: (301) 496-7728

The RFA label provided with the instructions must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

ONGOING PROGRAM ANNOUNCEMENTS

PREVENTION OF GALLSTONES

P.T. 34; K.W. 0715085, 0785055, 0765035, 0745055

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Dates: February 1, June 1, and October 1

PURPOSE

The Liver and Biliary Diseases Program of the Division of Digestive Diseases and Nutrition (DDDN) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) supports both basic and clinical research, and related training activities, in diseases of the biliary system. The program is seeking to stimulate interest in both basic and clinical research directed toward the prevention of gallstones; the epidemiology, pathogenesis and prevention. Accordingly, applications are invited for regular research project grants, program project grants, FIRST awards, career development awards, and postdoctoral fellowships relating to but not limited to the following areas of interest.

Basic Research

- The cell biology of lipid and protein metabolism in the liver in normal and appropriate cholesterol gallstone models in order to understand cholesterol regulation, bile acid metabolism and nucleation-antinucleation factors.
- The role of phospholipid vesicles in transporting biliary cholesterol.
- The physiology of the gallbladder, and how its innervation, response to hormones, absorptive and secretory functions, and musculature contribute to the development of gallstones.

Pilot Studies

- Small studies, in both animal models and man, testing agents that may inhibit nucleation, such as desaturating bile acids, prostaglandin inhibitors, hydrocholeretic agents, hormonal stimulants of gallbladder contraction, diet.
- Determination of the rate of growth of gallstones in the naive gallbladder or in the gallbladder from which stones have been removed by either chemical or physical methods (recurrence rate).

Clinical Trials

- Epidemiological studies examining relatives of gallstone patients to explore a genetic link.
Drug intervention trials in high risk populations such as obese individuals on rapid weight loss regimens, native Americans, Mexican-Americans, etc.

Dietary interventions, possibly used as an adjunct to other preventive measures.

BACKGROUND

Gallstone disease constitutes a national health issue of sizable proportion: an estimated 20 million individuals in the United States have gallstones and 500,000 are operated on yearly at a cost of approximately 2.5 billion dollars, excluding the cost of lost productivity. With the widespread use of a non-invasive, simple diagnostic test for gallstone disease (ultrasound), the presence of choleliths in the gallbladder and bile ducts are being discovered earlier. The technique also offers a valuable opportunity to obtain data relevant to the prevention of gallstone formation in man. The topic of gallstone prevention was the subject of a two day advisory meeting held in Bethesda, Maryland on July 29-30, 1986 to assist the Division of Digestive Diseases and Nutrition, NIDDK, in assessing promising areas of research. A summary of this meeting has appeared in Hepatology, Vol.7, No.5, 1987 (Sept/Oct issue). For discussion purposes, prevention was considered as primary, secondary or tertiary. Primary prevention was considered to be the inhibition of formation of stones in persons who have not previously had gallstones. Secondary prevention might be considered as the successful management of silent gallstones; e.g. the prevention of their clinical complications by dissolving them, flushing them out of the gallbladder with choleretics or preventing their further growth. Tertiary prevention might be considered as the prevention of gallstone recurrence once chemical or physical removal of gallstones had taken place. Primary prevention was the main topic of the meeting, although some ideas relevant to secondary and tertiary prevention also emerged.

The topics discussed at the aforementioned advisory meeting were: (1) epidemiology and natural history; (2) risk factors; (3) formation of supersaturated bile; (4) nucleation; (5) prevention of supersaturated bile; and (6) prevention of nucleation.

MECHANISMS OF SUPPORT AND REVIEW PROCEDURE

Applications considered appropriate responses to this announcement include the traditional research project grant (R01), the program project grant after prior consultation with the staff contact listed (P01), the FIRST award (R29), the Individual National Research Service Award (F32), and the following Career Development awards: the Research Career Development Award (K04), the Clinical Investigator Award (K08) and the Individual Physician Scientist Award (K11). The specific application forms (PHS 398, rev.9/86 for everything except the F32 which requires Form PHS 416-1) are in the business or grants and contracts offices of most academic and research institutions or may be obtained from:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
Bethesda, Maryland 20892
Telephone: (301) 496-7441

Applicants from institutions which have a General Clinical Research Center (GCRC) funded by the NIH Division of Research Resources may wish to identify the Center as a resource for conducting the proposed research. In such a case, a letter of agreement from the Program Director of the GCRC should be included with the application material.

Applications received in response to this announcement will be reviewed on a nationwide basis in competition with other applications and in accordance with the usual assignment and review procedures of the National Institutes of Health peer review procedures. The initial review for scientific and technical merit will be by an appropriate study section of either the Division of Research Grants (R01, R29, F32, K04) or NIDDK (P01, K08, K11). Secondary review will be by the National Diabetes and Digestive and Kidney Diseases Advisory Council. Funding decisions will be based upon relative scientific merit, program relevance and the availability of appropriated funds.

APPLICATION PROCEDURE

Applications will be accepted on an indefinite basis in accordance with the receipt, Initial Review Group, National Advisory Council, and earliest possible beginning dates specified in the pertinent application kits.
On the first (face) page, item 2, of the application, the word "Yes" should be checked and the phrase "RESPONSE TO NIDDK (DDDN) ANNOUNCEMENT ON PREVENTION OF GALLSTONES" should be typed in the space provided. Additionally, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement.

The original and six copies of the application should be sent or delivered to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892

STAFF CONTACT

For further information concerning this announcement and the mechanisms of support for research and training available in this connection, investigators are encouraged to contact:

Sarah C. Kalser, Ph.D.
Director
Liver and Biliary Diseases Program, NIDDK
National Institutes of Health
Westwood Building, Room 3A-17
Bethesda, Maryland 20892
Telephone: (301) 496-7858

In order to alert the Program to submission of applications, applicants are encouraged to send a letter of intent to Dr. Kalser or contact her at the telephone number listed above.

This program is described in the Catalog of Federal Domestic Assistance No. 13.848, Digestive Diseases and Nutrition Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RESEARCH CENTER GRANTS

P.T. 04; K.W. 0715120, 0710030, 0715095

National Institute of Mental Health

The National Institute of Mental Health announces a revised announcement for Acquired Immunodeficiency Syndrome (AIDS) Research Center Grants, MH-86-16, to establish additional AIDS Research Centers (AIDS/RC) to provide support for coordinated, multidisciplinary research programs on the mental health aspects of AIDS, ARC, and HIV infection. These grants will be supported by NIMH only. AIDS/RC grant support may be requested for up to 5 years. The overall aims of the center must be clearly defined for the period of support. Areas of future development should be indicated and justified. Applications must be complete when submitted; applicants should not assume that site visits will be made. Applications in response to this announcement will be accepted under the usual Public Health Service receipt dates for new applications, beginning February 1, 1988, and ending February 1, 1989. Potential applicants interested in obtaining technical assistance should contact:

Ellen Simon Stover, Ph.D., Deputy Director
Division of Basic Sciences
Room 11-105, Parklawn Building
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-3563

An institution planning to submit an application should notify:

Mrs. Edna Hardy-Hill, Chief
Research Development and Special Projects Review Branch
Division of Extramural Activities
Room 9C-15, Parklawn Building
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-6470